Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 10/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 9/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 9/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16757120 | 0.93 | MEN1 (0.37) | MEN1KMT2ASCN1ASCN5ASCN8A | |
| SCHEMBL29669070 | 0.92 | MEN1 (0.40) | MEN1KMT2ASCN1ASCN9AKDM4E | |
| SCHEMBL15466024 | 0.92 | MEN1 (0.40) | MEN1KMT2ASCN1ASCN9AKDM4E | |
| SCHEMBL29668680 | 0.92 | MEN1 (0.36) | MEN1KMT2ASCN1ASCN5ASCN8A | |
| SCHEMBL20095491 | 0.92 | TP53 (0.36) | MEN1KMT2ASCN1ASCN5ASCN8A | |
| SCHEMBL20238943 | 0.92 | MEN1 (0.36) | MEN1KMT2ASCN1ASCN5ASCN8A | |
| SCHEMBL18352237 | 0.92 | SCN1A (0.35) | SCN1ASCN5ASCN8ASCN9ASCN2A | |
| SCHEMBL16771614 | 0.91 | MEN1 (0.38) | MEN1KMT2ASCN1ASCN5ASCN8A | |
| SCHEMBL29668807 | 0.91 | KDM4E (0.42) | MEN1KMT2ASCN1ASCN9AKDM4E | |
| SCHEMBL20073007 | 0.90 | SCN1A (0.38) | SCN1ASCN5ASCN8ASCN9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983414-B1 | HYDROXYPYRROLIDINE-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4655291-A2 | N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS BACKGROUND | Merck Sharp & Dohme LLC (US) | 2025-12-03 | — | — | EP | disclosed |
| WO-2025245351-A1 | SUBSTITUTED ARYL SULFONAMIDES AND COMPOSITIONS AND USES THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2025-11-27 | — | — | WO | disclosed |
| US-12427159-B2 | Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME LLC (US) | 2025-09-30 | — | — | US | disclosed |
| WO-2025096637-A1 | SUBSTITUTED ARYL SULFONAMIDES FOR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2025-05-08 | — | — | WO | disclosed |
| WO-2024158653-A2 | N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS BACKGROUND | MERCK SHARP & DOHME LLC (US) | 2024-08-02 | — | — | WO | disclosed |
| EP-3541373-B1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3541373-B1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3389654-B1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3389654-B1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3043787-A2 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | Chromocell Corporation (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20160130239-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | CHROMOCELL CORPORATION (US) | 2016-05-12 | — | — | US | disclosed |
| US-20160130239-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | CHROMOCELL CORPORATION (US) | 2016-05-12 | — | — | US | disclosed |
| US-20160130239-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | CHROMOCELL CORPORATION (US) | 2016-05-12 | — | — | US | disclosed |
| WO-2016040315-A1 | SELECTIVE NAV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20160046617-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORPORATION (US) | 2016-02-18 | — | — | US | disclosed |
| EP-2968234-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | Chromocell Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015077905-A1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015080988-A1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2014151472-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130239-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | SCN7A, SCN1A, SCN10A | MEN1 3858/4885KMT2A 4444/4885SCN1A 2/4885 |
| US-20160046617-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | SCN7A, SCN10A, SCN2A | MEN1 4499/4885KMT2A 4076/4885SCN1A 5/4885 |
| US-12427159-B2 | Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels | TRPV1, SCN1A, SCN7A | MEN1 1845/4885KMT2A 2639/4885SCN1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.